Drug-Linker Conjugates for ADC
Drug-Linker Conjugates for Antibody Drug Conjugates (ADCs) comprise of an active cytotoxic drug and an appropriate linker. After linked to a monoclonal antibody, those conjugates can be used for making ADCs, which are targeted agents for cancer cells with high selectivity and cytotoxicity.
The drug units in drug-linker conjugates are cytotoxic agents (i.e. ADC cytotoxins or payloads) with antitumor activity and can be classified in DNA damaging agents and tubulin inhibitors. The most commonly used DNA damaging agents in ADCs are Duocarmycins, Pyrrolobenzodiazepines, Camptothecins and Daunorubicins/Doxorubicins, while the popular tubulin inhibitors are Auristatins and Maytansinoids. Besides, there are also many traditional cytotoxic agents can be used in ADCs.
ADC linkers currently undergoing clinical evaluation are mostly classified into two categories: cleavable and noncleavable. Cleavable linkers rely on processes inside the cell to liberate the toxin, and noncleavable linkers require proteolytic degradation of the antibody portion of the ADC for release of the cytotoxic molecule.
Drug-Linker Conjugates for ADC Isoform Specific Products
-
Drug-Linker Conjugates for ADC
(327)
View all products
-
Auristatin
(45)
View all products
-
Camptothecins
(33)
View all products
-
Daunorubicins/
Doxorubicins (5)View all products
-
Duocarmycins
(8)
View all products
-
Maytansinoids
(19)
View all products
-
Pyrrolobenzodiazepines
(5)
View all products
-
Traditional Cytotoxic Agents
(31)
View all products
-
Dual payloads
(5)
View all products
All Product Categories
-
Drug-Linker Conjugates for ADC Related Products (500)
Related Products (500)
-
Drug-Linker Conjugates for ADC Isoform Comparison
-
Boc-Lys-PEG8-N-bis(D-glucose)
0 ImagesCat. No.: HY-160247CAS No.: 2892350-30-8Boc-Lys-PEG8-N-bis(D-glucose) (compound 89-5) is a drug linker that can be used in the synthesis of antibody-drug conjugates (ADCs) extracted from patent WO2023280227A2.
-
MC-VC(S)-PABQ-Tubulysin M
0 ImagesCat. No.: HY-128910CAS No.: 2055896-86-9MC-VC(S)-PABQ-Tubulysin M is a synthetic ADC drug-linker conjugate composed of the tubulin polymerization inhibitor Tubulysin M (an ADC Cytotoxin) (HY-N7053) and MC-VC(S)- PABQ (an ADC linker) is connected. MC-VC(S)-PABQ-Tubulysin M is effective against multidrug-resistant lymphoma cell lines and tumors.
-
G3-VC-PAB-DMEA-Duocarmycin DM
0 ImagesCat. No.: HY-160143CAS No.: 2415664-00-3G3-VC-PAB-DMEA-Duocarmycin DM (Compound LD-1) is a duocarmycin-based linker molecule that can be used for ADC preparation..
-
Cyclopamine-COO-2-ethoxy-1,3-benzodioxole-O-C-Triazole-C5-AC
0 ImagesCat. No.: HY-181058Cyclopamine-COO-2-ethoxy-1,3-benzodioxole-O-C-Triazole-C5-AC is a drug-linker conjugate, with Cyclopamine (HY-17024) as its drug moiety. Cyclopamine-COO-2-ethoxy-1,3-benzodioxole-O-C-Triazole-C5-AC itself exhibits no significant anti-tumor activity. Cyclopamine-COO-2-ethoxy-1,3-benzodioxole-O-C-Triazole-C5-AC can be used for the synthesis of ADC molecules.
-
Mal-PEG4-NPV-PABC-DMEDA-tofacitinib
0 ImagesCat. No.: HY-182972CAS No.: 3110422-32-4Mal-PEG4-NPV-PABC-DMEDA-tofacitinib is a conjugate of a toxin and a linker, consisting of the JAK inhibitor Tofacitinib (HY-40354) and the linker Mal-PEG4-NPV-PABC-DMEDA (HY-182977). Mal-PEG4-NPV-PABC-DMEDA-tofacitinib can be used for the synthesis of ADC molecules.
-
BLD1102
0 ImagesBLD1102 is a linker-load conjugate (Drug-Linker Conjugates for ADC) consisting of a DNA topoisomerase I inhibitor BCPT02 and a protease-cleavable linker. BLD1102 can be used to synthesize ADCs. BLD1102 can be used in cancer research.
-
Mal-N(Me)-C6-N(Me)-PNU-159682
0 ImagesCat. No.: HY-171509CAS No.: 2682939-57-5Mal-N(Me)-C6-N(Me)-PNU-159682 (Compound 27), an agent-linker conjugate for ADC, consists the ADC linker Mal-N(Me)-C6-N(Me) and a potent ADC cytotoxin PNU-159682. Mal-N(Me)-C6-N(Me)-PNU-159682 (Compound 27) selectively delivers the payload to CD46-expressing cells, where the linker is cleaved by cathepsin B to release PNU-159682, inducing DNA damage and apoptosis. Mal-N(Me)-C6-N(Me)-PNU-159682 shows durable tumor regression in xenograft (PDX) models of non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).
-
Mal-Val-Ala-PAB-N(SO2Me)-Exatecan TFA
0 ImagesCat. No.: HY-159072APurity: 98.01%Mal-Val-Ala-PAB-N(SO2Me)-Exatecan TFA is a conjugate of an ADC toxin Exatecan (HY-13631) and a linker Mal-Val-Ala-PAB-N(SO2Me). Mal-Val-Ala-PAB-N(SO2Me)-Exatecan TFA can be used for synthesis of ADC FZ-AD005. FZ-AD005 is a delta-like ligand 3 (DLL3, KD=58.3 pM) targeting ADC, that exhibits antitumor efficacy against SCLC cancer.
-
N-(Mal-PEG4)-N-(PEG4-Val-Cit-PAB-MMAF)-N-(PEG4-Val-Cit-PAB-Exatecan)
0 ImagesCat. No.: HY-177687N-(Mal-PEG4)-N-(PEG4-Val-Cit-PAB-MMAF)-N-(PEG4-Val-Cit-PAB-Exatecan) is a drug-linker conjugate for ADC (Drug-Linker Conjugate for ADC), consisting of a tubulin polymerization inhibitor MMAE (HY-15162) and a DNA topoisomerase I inhibitor Exatecan (HY-13631), and an ADC linker composition. N-(Mal-PEG4)-N-(PEG4-Val-Cit-PAB-MMAF)-N-(PEG4-Val-Cit-PAB-Exatecan) can be used for synthesis of ADCs and for cancer research.
-
Fmoc-Gly3-VC-PAB-MMAE
0 ImagesCat. No.: HY-153976Fmoc-Gly3-VC-PAB-MMAE is a Drug-Linker Conjugates for ADC. Fmoc-Gly3-VC-PAB-MMAE consists of Monomethyl auristatin E (HY-15162) and a linker.
-
DBCO-tag peptide P1
0 ImagesCat. No.: HY-P11316DBCO-tag peptide P1 is a cysteine-containing peptide tag. DBCO-tag peptide P1 selectively reacts with dibenzocyclooctyne (DBCO) to yield stable dibenzocyclooctenyl thioethers. DBCO-tag peptide P1 enables site-selective mEGFP labeling and antibody (such as Trastuzumab (HY-P9907)) labelling without impairing the protein binding function. DBCO-tag peptide P1 can be used for ADC synthesis and mEGFP labeling research.
-
Mal-Val-Cit-PABC-Dexamethasone
0 ImagesCat. No.: HY-186292CAS No.: 1285684-41-4Mal-Val-Cit-PABC-Dexamethasone is a conjugate of the glucocorticoid receptor agonist Dexamethasone (HY-14648) and a ADC linker, which can be used for the synthesis of antibody-drug conjugates (ADC). Mal-Val-Cit-PABC-Dexamethasone is designed to deliver immunosuppressants to monocytes and/or monocyte-derived cells in a targeted manner.
-
Val-Cit-PAB-DEA-Dxd TFA
0 ImagesCat. No.: HY-158137APurity: 99.11%Val-Cit-PAB-DEA-Dxd (Compound 81) TFA is a Drug-Linker Conjugates for ADC, which is composed of a linker and a toxic molecule Dxd (HY-13631D). Val-Cit-PAB-DEA-Dxd can be used for ADC synthesis.
-
Mal-Val-Ala-PAB-NMe-CH2CH2-O-CO-Dazostinag
0 ImagesCat. No.: HY-158351CAS No.: 2553412-83-0Mal-Val-Ala-PAB-NMe-CH2CH2-O-CO-Dazostinag is a drug-linker conjugate for ADC.
-
MC-PEG4-β-Glu-Baloxavir
0 ImagesCat. No.: HY-185765MC-PEG4-β-Glu-Baloxavir is a conjugate of a toxin molecule and a linker, with Baloxavir (HY-109025A) as the payload. Baloxavir is an effective and selective inhibitor of cap-dependent nucleases (CEN). Baloxavir inhibits the transcription and replication of viral RNA and has strong antiviral activity.
-
MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2CO-homocamptothecin analog
0 ImagesCat. No.: HY-183254CAS No.: 3053452-26-6MC-Gly-Gly-Phe-Gly-NH-CH₂-O-CH₂CO-homocamptothecin analog is a linker-payload conjugate, which can be used for the synthesis of ADCs.
-
GSC4903
0 ImagesSynonyms: 2-MSP(4-OMe)-5-HA-PEG8-VA-Exatecan2-MSP(4-OMe)-5-HA-PEG8-VA-Exatecan is a Drug-linker conjugates for ADC consisting of the ADC Cytotoxin Exatecan (HY-13631) and a linker. 2-MSP(4-OMe)-5-HA-PEG8-VA-Exatecan can be used for synthesis of ADCs.
-
N-(NHS-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan)
0 ImagesCat. No.: HY-177682N-(NHS-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan) is a drug-linker conjugate for ADC (Drug-Linker Conjugate for ADC), consisting of a tubulin polymerization inhibitor MMAE (HY-15162) and a DNA topoisomerase I inhibitor Exatecan (HY-13631), and an ADC linker composition. N-(NHS-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan) can be used for synthesis of ADCs and for cancer research.
